BioSpace News Archive

Xspray Pharma AB announced the results from drug interaction studies demonstrating that DASYNOC’s uptake into blood following oral dosing is not altered by the concomitant administration of omeprazole, a commonly prescribed PPI, while a significant reduction in the uptake of SPRYCEL was observed with the use of omeprazole.

As part of the federal $5 billion Project NextGen program, Battelle was awarded $6.1 million from the BARDA to advance human lung and airway tissue chip platform technology, also known as “organ on a chip.” The award is part of BARDA’s indefinite delivery/indefinite quantity contract with Battelle.

Revolution Medicines, Inc. and EQRx, Inc., announced that earlier , at their respective special meetings, Revolution Medicines and EQRx stockholders voted to approve Revolution Medicines’ proposed acquisition of EQRx.

Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission on track to complete in Q4 this year

AlloSource®, one of the largest allograft providers creating innovative tissue products to help surgeons heal their patients, today announced the first implant of AceConnex Pre-Sutured Fascia device for hip labral reconstruction and augmentation.

Telix Pharmaceuticals Limited advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference 2023.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, reported financial and operating results for the third quarter of 2023.

Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, provided third quarter 2023 financial results and business updates.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, reported financial results for the third quarter ended September 30, 2023 and provided recent corporate and clinical updates.

Fate Therapeutics, Inc. reported business highlights and financial results for the third quarter ended September 30, 2023.